(1) The PI considers that the patient is not suitable to participate the study or the patient may be unsafe if he participate the study, (2) Patients with serious liver disease, grade C according to child-pugh, (3) Patients with severe renal impairment (glomerular filtration rate <=30mL/min/1.73m2) or who have received continuous renal replacement therapy, hemodialysis or peritoneal dialysis, (4) Patients with severe anemia, Hgb < 60g/L. (5) Pregnant women or women with pregnancy test positive or breastfeeding women, (6) Patients with allergy history of Triazavirin or its components, (7) Confused to sign the informed consent, (8) Patients may be transferred to another hospital within 72h, (9) Received any experimental treatment for novel coronavirus infection within 30 days prior to screening.

(1) The PI considers that the patient is not suitable to participate the study or the patient may be unsafe if he participate the study, (2) Patients with serious liver disease, grade C according to child-pugh, (3) Patients with severe renal impairment (glomerular filtration rate <=30mL/min/1.73m2) or who have received continuous renal replacement therapy, hemodialysis or peritoneal dialysis, (4) Patients with severe anemia, Hgb < 60g/L. (5) Pregnant women or women with pregnancy test positive or breastfeeding women, (6) Patients with allergy history of Triazavirin or its components, (7) Confused to sign the informed consent, (8) Patients may be transferred to another hospital within 72h, (9) Received any experimental treatment for novel coronavirus infection within 30 days prior to screening.